On management of mild hypertension during pregnancy

淮静,杨慧霞

DOI: https://doi.org/10.3760/cma.j.cn113903-20220413-00363

2022-01-01

Abstract:It has been accepted that pregnant women should receive antihypertensive therapy when the blood pressure is ≥160/110 mmHg (1 mmHg=0.133 kPa). However, a consensus is yet to be reached worldwide regarding whether lowering blood pressure is required for pregnant women with mild hypertension (blood pressure <160/110 mmHg). Diagnosis and treatment of hypertension and pre-eclampsia in pregnancy: a clinical practice guideline in China (2020) recommends that pregnant women whose blood pressure are ≥140/90 mmHg should be treated with antihypertensive therapy. A recent study has shown that antihypertensive therapy for pregnant women with blood pressure over 140/90 mmHg could improve the pregnancy outcomes, providing further evidence for the recommendation in the 2020 guideline in China. Current studies have shown that the risk of adverse pregnancy outcomes increases in pregnant women with normal high blood pressure (130-139/80-89 mmHg), which indicates that effective management measures such as close monitoring should be conducted for this population, in order to reduce the adverse pregnancy outcomes.